From a visionary startup to Switzerland's premier investment house - discover the story of strategic growth, trusted partnerships, and unwavering excellence that defines Anza Holding GmbH.
Anza Holding GmbH was established on April 1, 1997, with a clear vision: to create Switzerland's most trusted investment house. Founded by visionary entrepreneurs in Grenchen, we began with a modest portfolio but ambitious goals. Our first major acquisition was a commercial property in Basel, marking the beginning of our real estate expertise.
Under the leadership of Nicholas Goh, we expanded rapidly across Switzerland. Key partnerships were formed with major Swiss banks and real estate developers. During this period, we completed our first €50M real estate portfolio and established our trademark management division, acquiring exclusive rights to premium brands across Europe.
Antonio Zaccaria joined as Director, bringing extensive European market expertise. We established strategic partnerships in Germany, Austria, and France. Our portfolio grew to €200M with major acquisitions in luxury residential developments and commercial complexes. The financial crisis of 2008 actually strengthened our position as we acquired undervalued premium assets.
We pivoted toward sustainability, becoming early investors in renewable energy. Our first major solar farm in the Swiss Alps generated 25MW. Partnerships with leading medical technology companies began, including investments in pharmaceutical research and diagnostic equipment manufacturing.
We embraced digital transformation, implementing AI-driven investment analysis and blockchain technology for secure transactions. Major partnerships with Swiss pharmaceutical giants like Roche and Novartis were established. Our sustainable energy portfolio expanded to 200MW capacity. COVID-19 pandemic actually accelerated our medical technology investments.
Today, we manage €2.8B in assets with 520MW renewable energy capacity. Our medical technology partnerships span 45+ companies. We've achieved a 94% success rate across 180+ premium projects. Recent acquisitions include luxury office towers in Zurich and advanced pharmaceutical research facilities, positioning us as Switzerland's premier investment house.